The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Aer is utilizing a novel approach to identify and treat mucus plug-high COPD patients. Specifically, AER-01-002 will enroll 100 patients with moderate to severe COPD who are mucus plug-high.

HealthDay News — There is a bidirectional association between rheumatoid arthritis (RA) and chronic obstructive pulmonary ...

Turmeric's active compound, curcumin, is a potent anti-inflammatory and antioxidant that can help with conditions like ...

Your COPD is considered to be moderate. Your FEV1 is between 30% and 49% of the normal predicted values, and your FEV1/FVC is less than 70%. In this stage, you may experience shortness of breath ...

Although no cause of death or further details were given, the news comes months after Lynch announced he had been living with ...